Eva Rohde, MD, Medical University Salzburg, Salzburg, Austria, provides an overview of the current landscape of research into extracellular vesicle (EV)-based therapeutics. She notes that in the last decade, the field has moved from basic, discovery research towards translation into the clinic, with a number of approaches currently being evaluated in clinical trials. Dr Rohde describes a number of EV-based therapeutic strategies under investigation, including the use of mesenchymal stromal cell (MSC)-derived EVs in neurodegenerative disorders, as well as the use of EVs in bone and tendon regeneration. This interview took place during the International Society for Cell & Gene Therapy (ISCT) Annual Meeting 2021.
Eva Rohde is CEO of PMU Innovations GmbH., Salzburg, Austria. Eva Rohde is a Medical Consultant of MDimune Inc., Seoul, Korea.